长春高新（000661）技术产业(集团)股份有限公司(以下简称"长春高新")近日发布2024年年报，公司实 现营业收入134.66亿元，较上年同期降低7.55%；实现归属于上市公司股东的净利润25.83亿元，较上年 同期降低43.01%。这是近十年来，长春高新营收和净利润首次均出现同比下滑。 长春高新主营业务为生物制药及中成药的研发、生产和销售，辅以房地产开发等业务，并形成了长春金 赛药业有限责任公司(以下简称"金赛药业")、长春百克生物科技股份公司(以下简称"百克生物")、吉林 华康药业股份有限公司(以下简称"华康药业")、长春高新房地产开发有限责任公司(以下简称"高新地 产")"四驾马车"的发展格局。2024年，这四大子公司中，有3家业绩均出现下滑。 "现金奶牛"金赛药业净利润下滑超40% 从收入结构来看，长春高新仍高度依赖子公司金赛药业的生长激素。2024年，金赛药业实现收入106.71 亿元，较上年同期降低3.73%，占长春高新总营收的比例达79.24%；实现归属于母公司所有者的净利润 26.78亿元，较上年同期降低40.67%。 金赛药业是全球少数拥有粉针剂、水针剂、长效水针剂三代生长激素产品的企业 ...

Core Insights - The company reported a significant decline in revenue and net profit for 2024, primarily due to reduced sales of the shingles vaccine [1] - The nasal spray flu vaccine showed strong performance, while the shingles vaccine faced short-term sales pressure [1][2] - The company is actively advancing its R&D pipeline with multiple products achieving key milestones [2] - Profitability has decreased, with overall gross margin and net margin declining compared to the previous year [1] Financial Performance - In 2024, the company achieved revenue of 1.23 billion yuan, a decrease of 32.6%, and a net profit of 230 million yuan, down 53.7% [1] - For Q1 2025, revenue was 160 million yuan, a decline of 40.0%, with a net profit of 1 million yuan, down 98.2% [1] - The shingles vaccine generated revenue of 250 million yuan, a decrease of 71.5%, while the chickenpox vaccine revenue was 840 million yuan, an increase of 2.2% [1] - The nasal spray flu vaccine revenue reached 140 million yuan, an increase of 15.4% [1] - Overall gross margin for 2024 was 85.4%, down 4.8 percentage points, and net margin was 18.9%, down 8.6 percentage points [1] R&D Progress - The company invested 160 million yuan in R&D in 2024, accounting for 12.7% of revenue [2] - Key advancements include the acceptance of the liquid nasal spray flu vaccine application, completion of Phase I clinical trials for rabies monoclonal antibody, and initiation of Phase I/II clinical trials for tetanus monoclonal antibody [2] - Clinical trial approvals were obtained for HSV-2 mRNA vaccine and Hib vaccine, while the recombinant shingles vaccine and adjuvanted flu vaccine have submitted IND applications [2] Earnings Forecast - The company projects EPS of 0.6 yuan, 0.68 yuan, and 0.75 yuan for the years 2025, 2026, and 2027 respectively [3]

Group 1: General Information - The research was conducted on April 21, 2025, with the target company being Baike Biotech, which belongs to the biopharmaceutical industry [1][8] - Participating institutions include securities companies, investment companies, fund management companies, and asset management companies such as Guolian Minsheng Securities, Beijing Chengsheng, and Boyuan [2][9] Group 2: Company Performance - In 2024, the company's operating income was 1.2290841 billion yuan, a year - on - year decrease of 32.64%; net profit attributable to shareholders was 232.0938 million yuan, a decrease of 53.67%; and net profit after deducting non - recurring gains and losses was 229.8104 million yuan, a decrease of 53.42% [18] - In Q1 2025, operating income was 162.2905 million yuan, a year - on - year decrease of 39.96%; net profit attributable to shareholders was 1.0643 million yuan, a decrease of 98.24%; and net profit after deducting non - recurring gains and losses was - 3.412 million yuan, a decrease of 105.71% [18] - In 2024, varicella vaccine sales accounted for slightly over 65% of operating income with a slight increase; herpes zoster vaccine sales accounted for slightly over 20%; and nasal spray influenza vaccine had a slight year - on - year increase [19] - The company plans to distribute a cash dividend of 1.69 yuan per 10 shares (tax - included) in 2024, totaling 69.9081 million yuan (tax - included), accounting for 30.12% of the net profit attributable to shareholders [19] Group 3: Market and Strategy - The domestic herpes zoster vaccine penetration rate is still low. With the aging population, raising public awareness of the disease is crucial [19] - In 2025, the company will upgrade its marketing model, maintain its leading position in the varicella vaccine market, and expand the herpes zoster and influenza vaccine markets through various means [19][23] - The varicella vaccine is a non - immunization program vaccine. The company will continue to promote it for people over 12 years old to find new growth points [20] Group 4: International Market - The company's vaccine products are sold in countries such as India, Indonesia, Pakistan, Ghana, and Afghanistan. In 2024, varicella vaccine was exported to Afghanistan, and herpes zoster vaccine was first exported to Colombia [20] - The company is advancing the registration of varicella vaccine in Russia and expanding international sales channels through cooperation with multiple parties [20][21] Group 5: R & D Pipeline - Multiple R & D pipeline products have made key progress, including the acceptance of the listing application for liquid nasal spray influenza vaccine, and various stages of clinical trials for other products [21] - The company is also promoting R & D projects such as RSV monoclonal antibody and vaccine, and Alzheimer's disease therapeutic vaccine [21] Group 6: Marketing and Expenses - In 2024, the company established partnerships with various platforms for digital marketing of herpes zoster vaccine. As of January 1, 2025, the county - level coverage rate was about 60% [21][22] - In 2025, R & D investment is expected to increase significantly, and the sales expense ratio is expected to rise first and then fall [22]